Ethyl eicosapentaenoic acid - Amarin
Alternative Names: VAZKEPA; AMR-101; Eicosapentaenoic acid ethyl ester - Amarin; Eicosapentanoic acid ethyl ester; EPA-Vascepa; Ethyl eicosapentaenoate; Ethyl eicosopentaenoate; Ethyl icopenate; Ethyl-EPA; Icosapent ethyl - Amarin Corporation; Icosapentaenoic acid ethyl ester; LAX-101; LAX-101c; Miraxion™; Ultra-pure eicosapentaenoic acid; Ultra-pure EPA; Ultra-pure ethyl ecosapentaenoic acid; Ultra-pure ethyl EPA; Vascepa; VAZKEPA; VazkepaLatest Information Update: 23 Jul 2024
At a glance
- Originator Scarista
- Developer Amarin Corporation; Biologix FZCo; Eddingpharm; HLS Therapeutics; University of Leeds; Yorkshire Cancer Research
- Class Antidementias; Antidepressants; Antihyperlipidaemics; Antineoplastics; Antiplatelets; Antivirals; Eicosanoids; Esters; Omega 3 fatty acids; Reactive oxygen species; Small molecules; Vascular disorder therapies
- Mechanism of Action Diacylglycerol O-acyltransferase inhibitors; Phospholipase A2 inhibitors; Platelet aggregation inhibitors; Triglyceride modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Hypertriglyceridaemia
- Registered Cardiovascular disorders
- Phase III Colorectal cancer; COVID 2019 infections; Liver metastases
- Discontinued Huntington's disease; Major depressive disorder; Memory disorders; Parkinson's disease; Psychotic disorders
Most Recent Events
- 17 Jul 2024 Amarin Corporation announces intention to launch ethyl eicosapentaenoic acid for Hypertriglyceridaemia in Portugal at the beginning of August 2024
- 03 Apr 2024 Amarin has patent pending from the 2033 patent family for ethyl eicosapentaenoic acid in Europe
- 03 Apr 2024 Amarin has patent protection for ethyl eicosapentaenoic acid in Europe